The clinical trial for the Neo-Urinary Conduit moves forward to continue to help bladder cancer patients:
"Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay. The protocol for this initial clinical trial calls for each of the first few patient implantations to occur at least eight weeks after the previous patient surgery. The surgical procedure may be modified in subsequent patients based on the experience gained by the prior patient(s) enrolled. No modifications to the protocol have been made based on the experience with the first patient.
"We are very encouraged by the response we have seen so far in our first patient and we look forward to continuing to advance this trial and to enrolling additional patients," commented Sunita Sheth, M.D., Vice President and Chief Medical Officer at Tengion."
Read More: http://www.mdtmag.com/News/Feeds/2010/11/device-sectors-surgery-tengion-...